Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Biotech

How does Biogen move beyond its Alzheimer’s drug blowup? Listen for the clues

By Adam Feuerstein

Nerve growth factor protein complex
Biotech

Disappointing trial results dim hopes for a new class of pain drugs

By Damian Garde

Arrakis CEO Michael Gilman
Biotech

Drugging the undruggable and other challenges on the road to targeting RNA with pills

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

Play
The Readout LOUD

Listen: Democratizing CRISPR, drugging the undruggable, and reading pharma’s fine print

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Biotech

A biotech startup’s lofty goal: Kill cancer with pills that target RNA instead of proteins

By Adam Feuerstein

Unfinished bridge
Biotech

When a new biotech’s drug pipeline is more of a ‘hypeline’

By Kate Sheridan

Nasdaq
Biotech

Watch this company: Turning Point Therapeutics shares pop 57% after IPO

By Matthew Herper

Man coughing
Biotech

How one company thinks unraveling cough can provide a new way to treat pain

By Damian Garde

Mission Bay construction
Go West

San Francisco’s Mission Bay neighborhood was supposed to be a thicket of biotech. What went wrong?

By Rebecca Robbins

Pharmalot

Pharmalittle: Stronger warnings urged for Amgen’s osteoporosis drug; prices in drug ads can be jarring

By Ed Silverman and Elizabeth Cooney

Daphne Koller
Biotech

In a test for AI, a buzzy machine learning startup inks drug discovery deal with Gilead

By Matthew Herper and Rebecca Robbins

STAT SPOTLIGHT
Biotech

Startup Spotlight: Flagship reveals Kintai Therapeutics — yet another microbiome company

By Kate Sheridan

Liver illustration
Biotech

The NASH race: A fleeting frontrunner, a stumbling giant, and others in biotech look to the finish line

By Adam Feuerstein

Biotech

Latest Alnylam data underscores positive results for new RNAi drug candidate, at least for some patients

By Kate Sheridan

JUST MERGERED
Pharma

The Bristol-Celgene merger is approved. Here are 8 challenges ahead

By Damian Garde and Adam Feuerstein

Play
The Readout LOUD

Listen: Trump’s drug pricing foot soldier, Gilead’s uncertain future, & transpacific angst

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Millions of dollars
Biotech

AskBio’s $235 million financing provides clues to the direction of gene therapy investment

By Matthew Herper

Flora of small intestine
Biotech

As microbiome companies develop new therapies, it’s academics who are doing the heavy lifting

By Kate Sheridan

Biotech

Gilead Sciences to lay off one-fifth of sales force as financial pressures build

By Adam Feuerstein

Biotech

Archived chat: Biotech, AMA-style

By Adam Feuerstein and Matthew Herper

Duchenne muscular dystrophy Histopathology
Biotech

Audentes Therapeutics to develop gene therapies for two types of muscular dystrophy, including Duchenne

By Matthew Herper

Alnylam RNAi
Biotech

Regeneron to invest $800 million in Alnylam, betting on drug-making technique enabled by a Nobel-winning discovery

By Matthew Herper

Lot of white capsules on a blue background.
Biotech

6 things to know before the readout of BioCryst Pharma’s pivotal clinical trial

By Adam Feuerstein

Play
The Readout LOUD

Listen: Cheaper insulin, the next Juul, and diagnosing disease with sound

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Scorecard
Biotech

The biotech scorecard for the second quarter: 18 stock-moving events to watch

By Adam Feuerstein

Patrick Soon-Shiong
Pharmalot

A small drug maker accuses Soon-Shiong of masterminding a ‘catch-and-kill’ scheme

By Ed Silverman

Bacteriophage illustration
Biotech

Can CRISPR improve on nature’s own bacteria-killing phages?

By Eric Boodman

Biotech

It’s only test tubes and mice, but Rubius Therapeutics hails first new data on red blood cell-derived cancer drugs

By Adam Feuerstein

Biotech

In biotech’s biggest hub, companies open their labs to an unlikely inspector: the city’s veterinarian

By Kate Sheridan

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy